This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07351045 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Hoffmann-La Roche |
| Enrollment | 2,000 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity or Overweight |
| Interventions | Placebo; Enicepatide |
| Start | Mar 16, 2026 |
| Primary completion | Jul 24, 2028 |
| Study completion | Aug 28, 2028 |
| Results posted | Not yet |
| Registry last updated | Nov 9, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent (%) Change from Baseline in Body Weight at Week 72 | Baseline through Week 72 |
43 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Enicepatide (CT-388)
- Enicepatide: Phase 3 Trial (NCT07670416)
- Enicepatide: Phase 3 Trial (NCT07351058)
- Enicepatide: Phase 2 Trial in Obesity (NCT06525935)
- Enicepatide: Phase 2 Trial (NCT06628362)
- Enicepatide: Phase 1 Trial in Healthy Volunteers (NCT07626515)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.